Biotech Values

[jq1234]

“Eli Lilly and several of its competitors are willing to spend hundreds of millions of dollars on what is essentially a massive lottery ticket,” Anderson said. “If their drugs are successful in delaying the progression of Alzheimer’s disease, they could end up making Lipitor look like a mid-sized product,” he said in a note to clients sent yesterday. Sales of solanezumab could reach $9 billion by 2020, he said.

How stupid are some analysts? Do they even read their own writings? They should be unemployed.

I can write a few:

If Dimebon worked, PFE would have made great deal with MDVN to replace Lipitor revenue lost to generic. If VRUS nuke works, and generates $14 billion peak sale, GILD would have made a great deal! duh?